2 ms·
It reads to me like these medications are _not_ going to be classified as "over the counter." Even though they will not require a prescription, that's the whol
by jrochkind1 8y ago
It reads to me like these medications are _not_ going to be classified as "over the counter." Even though they will not require a prescription, that's the whole point.
I wonder if the regulations are written in some way to allow them to keep charging prescription prices without a prescription. The article definitely suggests it's a new "status", not merely making more things OTC.
From the OP:
> Finding a way to expand access to widely used prescription drugs has been a goal of regulators in recent years.
> The FDA explored the idea of a “behind-the-counter” designation in 2007 that would have required interaction with a pharmacist. The Government Accountability Office in a 2009 report on the proposal asked whether consumers would end up paying more for their drugs since nonprescription medications typically aren’t covered by insurance."
Note, since they aren't typically _covered by insurance_. A new designation that would be covered by insurance, fit into insurance schedules under "prescription", but not actually require a prescription -- hey, "everyone" wins!
From: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm613692.htm https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/u...
"Currently, nonprescription drugs can be marketed under either of two regulatory pathways: the Over-the-Counter (OTC) Drug Review (OTC Monograph Process) or the New Drug Application (NDA) process, and there are different requirements under each system. Today’s new FDA draft guidance, Innovative Approaches for Nonprescription Drug Products, applies to drugs under the NDA process and is intended to extend that NDA pathway to include therapeutic indications that have not, historically, been available for use without a prescription."
The (very brief) draft guidance itself: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM613666.pdf https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegula...